DIVISLAB - Divi's Laboratories Limited
NSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Hyderabad,
India
Type: Equity
DIVISLAB price evolution
DIVISLAB
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33366.3 | $12147.6 | ||
| Short term investments | $15269 | |||
| Net receivables | $18396.7 | $25283.4 | ||
| Inventory | $29699.3 | $28286.2 | ||
| Total current assets | $84298.6 | $83515 | ||
| Long term investments | $745.3 | $720.1 | ||
| Property, plant & equipment | $48664.8 | $47874.9 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $135182.6 | $133747.1 | ||
| Current liabilities | ||||
| Accounts payable | $6749.9 | $7957 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $9141.2 | $11955.5 | ||
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $13835.8 | $16465.3 | ||
| Shareholders' equity | ||||
| Retained earnings | $115797 | |||
| Other shareholder equity | $120815.9 | $155.1 | ||
| Total shareholder equity | $121346.8 | $117281.8 | $117281.8 | $99291.9 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12147.6 | $20303.2 | $431.5 | $130 |
| Short term investments | $15269 | $546.4 | $110.1 | |
| Net receivables | $25283.4 | $17783 | $15990.4 | $12964.9 |
| Inventory | $28286.2 | $21452.3 | $18638.6 | $17723.4 |
| Total current assets | $83515 | $61747.1 | $46798.3 | $46500.5 |
| Long term investments | $720.1 | $0.1 | $0.1 | $5472.6 |
| Property, plant & equipment | $47874.9 | $44095.4 | $36979.4 | $25756.3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $133747.1 | $107740.7 | $85357 | $80382.5 |
| Current liabilities | ||||
| Accounts payable | $7957 | $7632 | $5907.2 | $4922.6 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $11955.5 | $11124.6 | $9268.3 | $8467.5 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $16465.3 | $14794.6 | $12257.8 | $10811 |
| Shareholders' equity | ||||
| Retained earnings | $115797 | $91480.1 | $71635.6 | $68163.5 |
| Other shareholder equity | $155.1 | $136.3 | $133.9 | $78.3 |
| Total shareholder equity | $117281.8 | $92946.1 | $73099.2 | $69571.5 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $18545.4 | $22545.2 | $25185.3 | $24932.4 |
| Cost of revenue | $6746.3 | $8119.6 | $10319.5 | $8315.5 |
| Gross Profit | $11799.1 | $14425.6 | $14865.8 | $16616.9 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $2321.2 | $2463.8 | $2676.9 | $2446.2 |
| Total operating expenses | $13192.3 | $14914.8 | $14929.6 | $14728.7 |
| Operating income | $5353.1 | $7630.4 | $10255.7 | $10203.7 |
| Income from continuing operations | ||||
| EBIT | $5353.1 | $7630.4 | $10255.7 | $10203.7 |
| Income tax expense | $1216.2 | $1492.9 | $1811 | $1314.2 |
| Interest expense | -$1.7 | -$1.3 | -$2.3 | |
| Net income | ||||
| Net income | $4936 | $7020.1 | $8946.4 | $9022.4 |
| Income (for common shares) | $4936 | $7020.1 | $8946.4 | $9022.4 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $89599.2 | $69694.7 | $53944.7 | $49462.7 |
| Cost of revenue | $31604.7 | $24718.2 | $22455.5 | $19240.8 |
| Gross Profit | $57994.5 | $44976.5 | $31489.2 | $30221.9 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $9570.9 | $8366.9 | $6316.8 | $5519 |
| Total operating expenses | $53873.5 | $43547.1 | $37552.4 | $32376.4 |
| Operating income | $35725.7 | $26147.6 | $16392.3 | $17086.3 |
| Income from continuing operations | ||||
| EBIT | $35725.7 | $26147.6 | $16392.3 | $17086.3 |
| Income tax expense | $7230.5 | $6817.5 | $4429.2 | $5023.3 |
| Interest expense | -$3.7 | -$3.9 | -$55.4 | -$21.2 |
| Net income | ||||
| Net income | $29604.5 | $19842.9 | $13765.4 | $13527.4 |
| Income (for common shares) | $29604.5 | $19842.9 | $13765.4 | $13527.4 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Net income | $4936 | $7020.1 | $8946.4 | $9022.4 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | ||||
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Net income | $29604.5 | $19842.9 | $13765.4 | $13527.4 |
| Operating activities | ||||
| Depreciation | $3083.3 | $2526.2 | $1833.8 | $1662.4 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $19118 | $19469.3 | $12159.4 | $9543 |
| Investing activities | ||||
| Capital expenditures | -$7132 | -$9101.9 | -$11832.1 | -$7330.7 |
| Investments | -$15485.3 | $9281.6 | $10562.9 | -$429.5 |
| Total cash flows from investing | -$21949.2 | $751.3 | -$834.7 | -$6854 |
| Financing activities | ||||
| Dividends paid | -$5309.4 | -$8495 | -$2654.7 | |
| Sale and purchase of stock | ||||
| Net borrowings | -$11.4 | -$340.2 | -$612 | $776 |
| Total cash flows from financing | -$5324.4 | -$348.9 | -$10914.2 | -$2459.4 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8155.6 | $19871.7 | $410.5 | $229.6 |
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $91.21B |
|---|---|
| EBITDA | N/A |
| EBIT | $33.44B |
| Net Income | $29.92B |
| Revenue Q/Q | -6.69% |
| Revenue Y/Y | 22.63% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | 26.30% |
| Debt/Equity | 0.14 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.22 |
| Quick ratio | 5.97 |